Kura Oncology surges on initial sales of new leukemia therapy

Kura Oncology (NASDAQ:KURA) reported $5.8 million in net product revenue for the first quarter of 2026, marking the first full period of sales for its acute myeloid leukemia treatment, Komzifti.

The San Diego-based biotechnology company saw 85 new patient starts and 157 total prescriptions for the drug, also known as ziftomenib, while achieving more than 93% payer coverage across more than 12 million lives.

The company posted total collaboration revenue of $12.5 million, though it reported a net loss of $73.3 million for the quarter.

Management attributed the loss to increased spending on research and development as well as selling, general, and administrative expenses associated with the commercial rollout.

Despite the quarterly deficit, Kura ended the period with $580.8 million in cash, equivalents, and short-term investments.

Kura expects its current capital, bolstered by $180 million in anticipated collaboration payments, to fund operations through the release of topline results from its Phase 3 KOMET-017 trial.

That data, which focuses on ziftomenib in patients with a specific genetic mutation of AML, is expected in early 2028.